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Abstract
Background: Bronchiolitis is the most common reason for admission of infants to hospital in developed countries. 
Fluid replacement therapy is required in about 30% of children admitted with bronchiolitis. There are currently two 
techniques of fluid replacement therapy that are used with the same frequency-intravenous (IV) or nasogastric (NG).
The evidence to determine the optimum route of hydration therapy for infants with bronchiolitis is inadequate. This
randomised trial will be the first to provide good quality evidence of whether nasogastric rehydration (NGR) offers
benefits over intravenous rehydration (IVR) using the clinically relevant continuous outcome measure of duration of
hospital admission.
Methods/Design: A prospective randomised multi-centre trial in Australia and New Zealand where children between 
2 and 12 months of age with bronchiolitis, needing non oral fluid replacement, are randomised to receive either 
intravenous (IV) or nasogastric (NG) rehydration.
750 patients admitted to participating hospitals will be recruited, and will be followed daily during the admission and
by telephone 1 week after discharge. Patients with chronic respiratory, cardiac, or neurological disease; choanal atresia;
needing IV fluid resuscitation; needing an IV for other reasons, and those requiring CPAP or ventilation are excluded.
The primary endpoint is duration of hospital admission. Secondary outcomes are complications, need for ICU
admission, parental satisfaction, and an economic evaluation. Results will be analysed using t-test for continuous data,
and chi squared for categorical data. Non parametric data will be log transformed.
Discussion: This trial will define the role of NGR and IVR in bronchiolitis
Trail registration: The trial is registered with the Australian and New Zealand Clinical Trials Registry - 
ACTRN12605000033640
Background
Bronchiolitis is a disease of the lower respiratory tract
with peak incidence in the winter. It is the leading cause
of hospitalisation during the first year of life and is a
major cause of morbidity and mortality [1-5]. Victorian
state-wide data for the calendar year 2006 reveal 2280
admissions for bronchiolitis, with an average length of
stay of 3.2 days. One hundred sixty eight (7.4%) patients
were admitted to intensive care. The estimated cost of the
Victorian bronchiolitis hospital admissions for 2006 is
$8.1 million dollars (data supplied at personal request
from Victorian Admitted Episodes Dataset, Performance
Reporting & Analysis Unit, Department of Human Ser-
vices Victoria). In the United States of America bronchi-
* Correspondence: ed.oakley@southernhealth.org.au
1 Department of Emergency Medicine Monash Medical Centre, Clayton Rd, 
Clayton Victoria 3168 Australia
Full list of author information is available at the end of the article  BMC Pediatrics 2010, 10:37
http://www.biomedcentral.com/1471-2431/10/37
Page 2 of 8
o l i t i s  a c c o u n t s  f o r  2 1 %  o f  all hospital admissions for
children under 1 year of age, with an annual cost of $390
million dollars [5].
There are no clearly effective chemotherapeutic treat-
ments to improve the outcome of infants with bronchioli-
tis, so treatment is limited to oxygen, supportive care of
breathing, and fluid replacement therapy[1,2,6-10].
Maintaining hydration is an important component of the
care of infants with bronchiolitis. Fluid replacement ther-
apy is required in about 30% of children admitted with
bronchiolitis, due to reduced oral intake and evaporative
losses from increased respiratory effort and fever [11].
There are currently two techniques of fluid replace-
ment therapy, IV or NG. There is a lack of agreement on
which method of fluid replacement is most beneficial for
patients with bronchiolitis - we do not know which ther-
apy is better. They both have theoretical grounds for
superiority, but both also have a range of possible compli-
cations. As fluid replacement is such an important aspect
of the management of this common disease it is very
important that fluid therapy is evidence based.
Nasogastric fluid replacement (NGR) is effective and
has few complications. It provides the physiological bene-
fit of enteral hydration, which allows the body to absorb
the required amounts of water and solute. In children
with dehydration due to gastroenteritis, NGR is the treat-
ment of choice as it provides faster recovery, shorter hos-
p i t a l  s t a y  a n d  l o w e r s  t h e  c o s t  c o m p a r e d  t o  I V  f l u i d
replacement (IVR) [12,13]. A nasogastric tube (NGT) can
often be inserted more easily than an IV catheter, espe-
cially in infants with poor peripheral circulation due to
reduced oral intake. However, concerns have been raised
regarding the use of nasogastric tubes (NGT) in infants
w i t h  b r o n c h i o l i t i s .  T h e r e  m a y  b e  a n  i n c r e a s e d  r i s k  o f
aspiration in patients with bronchiolitis [14]. The partial
obstruction of the upper airway may compromise respi-
ratory function, [15-18] with some studies showing up to
a 50% increase in the work of breathing [16]. However
these studies have been mostly in young or preterm
infants and the ability to extrapolate these findings to
older infants with bronchiolitis is questionable.
Intravenous fluid replacement (IVR) is commonly used
in bronchiolitis[1]. However, accidental water intoxica-
tion and electrolyte imbalances are potential complica-
tions [10]. Up to 30% of children admitted with
bronchiolitis have been shown to have some degree of
hyponatraemia requiring vigilance with IV fluid adminis-
tration[19,20]. It has also been postulated that delaying
enteral nutrition will cause delay in recovery due to loss
of nutritional status, and that the persisting hunger may
make the children more irritable.
Kennedy et al (2005)[21] reviewed the evidence for
fluid replacement in children with bronchiolitis. The
authors report a wide variation in practice, with use of
NGR in many units. They conclude that "there is no good
quality evidence for or against the use of NGR in infants
with bronchiolitis. A randomised controlled trial is
needed." Vogel (2003) [22] described the management of
bronchiolitis admissions in New Zealand hospitals in
1998. There was a large variation in management
between hospitals, with between 6% and 64% of children
needing fluid replacement therapy receiving NGR.
We confirmed the wide variation of practice in Austra-
lia with a pilot study. As baseline data for our proposed
study, a survey of Australasian paediatric emergency phy-
sicians was undertaken in 2005, by the Paediatric
Research in Emergency Departments International Col-
laborative (PREDICT), a research collaborative of all ter-
tiary paediatric emergency departments and major mixed
emergency departments in Australia and New Zealand).
Of the 78 senior doctors surveyed at 11 sites (including all
tertiary paediatric emergency departments in Australia
and New Zealand), 48% reported using NGR and 52%
IVR as initial treatment in acute bronchiolitis. There were
no guidelines in any institution to determine which fluid
replacement therapy should be used in bronchiolitis [23].
There are no published trials directly comparing NGR
and IVR. The research available on NGR in bronchiolitis
comes from two small studies. In a case series of 37
infants with bronchiolitis, Sammartino (2002) [24] found
NGR was tolerated without incident. Two infants deteri-
orated as the illness progressed and removal of the NGT
did not help.
Smyth and Openshaw[10] in a Lancet  review article
conclude "Neither oxygen therapy, nor fluid replacement
strategies have been validated in large randomised con-
trolled trials, although the dangers of hyponatraemic
fluid overload are recognised. These treatment options
should be addressed in randomised controlled trials."
Further Smyth states that "Clinical trials of interventions
in bronchiolitis have been criticised for being too small
and focusing on short-term outcomes, rather than
reporting outcomes of interest to clinicians and parents,
such as length of hospital stay."
Davison et al [6] conclude in another recent review:
"There is an ongoing need for studies that are adequately
powered to identify therapies that may benefit critically
ill children with this disease (bronchiolitis). Because the
mortality associated with bronchiolitis is low, large multi-
centre trials that focus on continuous outcome measures
such as duration of mechanical ventilation and ICU or
hospital length of stay will provide the best opportunity
to demonstrate a clinical benefit with adequate statistical
power."
The evidence to determine the optimum route of
hydration therapy for infants with bronchiolitis is inade-
quate. This randomised trial will be the first to provide  BMC Pediatrics 2010, 10:37
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good quality evidence of whether NGR offers benefits
over IVR.
Methods/Design
Study Aims
The primary aim of this multicentre randomised trial is
to investigate whether the type of fluid replacement - NG
versus IV - affects the duration of hospital admission, in
children aged between 2 and 12 months admitted to hos-
pital with a clinical diagnosis of bronchiolitis. Secondary
aims are to undertake an economic appraisal, and to
determine the difference in the incidence of complica-
tions, duration of treatment and parental satisfaction for
the two treatments.
We hypothesise that there will be a difference in the
length of hospital stay between the two treatment modal-
ities.
Study Design and setting
This study is an open randomised trial comparing two
interventions. This study will take place in 6 paediatric
emergency departments and inpatient wards in Australia
and New Zealand.
Ethical considerations
The study has ethical approvement at all participating
sites. All parents/guardians are provided with both verbal
and written information about the study and written
informed consent is obtained prior to enrolment in the
trial.
The trial is overseen by a trial steering committee that
is responsible for the ethical and rigorous conduct of the
trial.
A data monitoring committee (with membership
entirely independent of the conduct of the trial) will mon-
itor adverse events and review outcomes and complica-
tions annually. They will report and make
recommendations to the trial steering committee. No for-
mal stopping rules are in place.
Subject Selection
Children satisfying the inclusion and exclusion criteria
who are admitted to the hospital will be eligible for the
study. Patients admitted to the ward with bronchiolitis
who deteriorate and need institution of hydration will be
eligible for randomisation. Figure 1 outlines the flow of
patients through the study.
Definition of Disease State
The eligible patients will be all children younger than 12
months and older than 8 weeks (corrected for prematu-
rity) presenting to the Emergency Department with bron-
chiolitis requiring hydration. The need for hydration will
be defined by a history of oral intake less than 50% in the
last 6 hours or signs of dehydration such as reduced urine
output, tachycardia (in the absence of fever), dry mucous
membranes, decreased skin turgor or sunken fontanelle.
Inclusion and Exclusion Criteria
Inclusion and exclusion criteria are shown in Additional
File 1. In order to keep the study group as homogeneous
as possible patients younger than 8 weeks were excluded
as the very young often have a different and more severe
clinical presentation and course of bronchiolitis. Children
older than 12 months were also excluded as other diagno-
s e s ,  i n  p a r t i c u l a r  a s t h m a  a s s u m e  a n  i n c r e a s i n g  r o l e ,
impacting on the identification and management of these
patients.
Patient randomisation
The patients will be randomised at the time they require
non oral fluid replacement. Randomisation will be strati-
fied by 2 age groups (2 months to less than 6 months, 6
months to less than 12 months) and by site. Randomisa-
tion will be blocked in 3 randomly allocated block sizes to
ensure concealment of allocation. Each site will have its
own set of opaque sealed randomisation envelopes.
These will have a reminder of inclusion and exclusion cri-
teria to be assessed before the envelope is opened.
Randomised treatments
Intravenous fluid replacement group
Topical anaesthetic cream will be used in accordance
with hospital policy to reduce the pain of IV insertion.
Insertion of the IV cannula will be at the site of anaes-
thetic cream application after 30-60 minutes. Size 22 or
24 gauge cannulae will be used for all cases. The fluid
used for hydration will be 0.45% Sodium Chloride with
2.5 or 5% dextrose. Ongoing fluid replacement will be
guided by the measured serum electrolytes (see "Data
Collection").
Nasogastric fluid replacement group
Insertion of the NGT will be by experienced personnel.
The nostril will be sprayed with local anaesthetic spray 2
minutes prior to NGT insertion. The tube will be mea-
sured from nares to epigastrium to determine depth of
insertion. Post insertion correct tube placement will be
confirmed by aspiration of stomach contents with pH < 4.
Failed aspiration or pH ≥4 should be repeated after 30
minutes. A repeated failure to confirm the presence of
the NGT in the stomach by these means requires an
abdominal/chest x-ray to be performed to confirm the
position of the tube prior to its use. If there is doubt about
the position of the tube after this it should be removed
and replaced. Tubes will be size: 6 French < 6 months of
age, and 8 French 6-12 months of age. NGR will be by
continuous infusion with a standard oral electrolyte solu-
tion for the first two hours, followed by expressed breast
milk or formula.  BMC Pediatrics 2010, 10:37
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For both groups All patients will be admitted to the
ward under the appropriate unit. Total fluid replacement
will not exceed 100% of normal daily requirements. Oral
feeds will be at the discretion of the clinical team and the
IV or NG fluid rate adjusted accordingly.
A parent satisfaction score will be obtained using a
standardised, five point Likert scale. The score will be
obtained daily from one parent or by agreement with
both parents if they are in attendance. A final "overall"
Figure 1 Patient identification and entry into CRIB study.
Patients presenting to 
emergency department 
meeting inclusion criteria 
Clinician decision to 
admit patient 
Clinician decision to 
discharge patient. No 
further study involvement 
Informed consent 
obtained 
Drinking adequately  Requiring non oral 
fluids 
Followed daily in ward until 
discharge by research team 
Randomised locally by 
opaque envelope 
(envelopes held in 
emergency department) 
Telephone review 1 
week post discharge 
No requirement for 
non oral fluids. 
No further study 
involvement 
Requires non oral 
hydration at some 
point in inpatient 
stay   BMC Pediatrics 2010, 10:37
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satisfaction score will be obtained immediately prior to
hospital discharge.
All patients will be followed up at 5 to 7 days post dis-
charge with a standard questionnaire to determine the
incidence of complications, or need for further medical
care.
Study Procedure
All patients will have all clinical observations entered into
a Clinical Report Form (CRF) by the nursing staff at the
time of performing the observations. All CRFs will be
checked daily by research staff while the participant is an
inpatient.
Clinical observations from nursing records
SpO2, respiratory rate, respiratory effort, and heart rate
will be measured at enrolment, at hourly intervals for the
first 2 hours then 2 hourly. These will allow comparison
of groups by severity of disease at enrolment, and ensure
any clinically relevant complications are captured.
Oxygen administered (L/min for nasal cannulae or %O2
f o r  h e a d  b o x )  w i l l  b e  d o c u m e n t e d  f o r  e a c h  s h i f t .  T h e
times oxygen is commenced and ceased will be docu-
mented. This will allow accurate capture of the duration
of oxygen therapy. Type, route and volume of fluid
administered will be recorded, with hourly, shift, and
daily totals. This allows assessment of fluid requirements
and cross referencing volumes of fluid infused. Hydration
status of the patients will be measured using urine output
(with shift and daily totals) and weight (measured at the
time of admission, and then daily).
Complications recorded will include: episodes of
apnoea and bradycardia (lasting more than 20 seconds);
all episodes where the SpO2 was recorded at < 90%; and
the need for replacement of, or problems with the IV can-
nula or NGT.
The need for and duration of ICU admission will be
documented. Duration of hospital admission will be doc-
umented and checked by calculation from the hospital
admissions and discharge system.
Laboratory investigations
Electrolytes, urea and creatinine, and glucose levels will
be measured when inserting the IV line. Electrolytes will
be repeated 6-8 hours after commencement of therapy in
the intravenous therapy group (as an accepted standard
in IV fluid management); and daily thereafter. Blood sam-
pling may be by draw back on IV cannulae with discard-
ing of 2 mls of blood or alternatively sampling by IV
access or capillary blood sample at the discretion of phy-
sician managing patient. All testing of electrolyte levels in
patients with iv fluids and non testing in patients with
NG fluids are in line with current local recommended
practice and represent standard care at the participating
hospitals [23]. No additional blood tests will taken for the
purpose of this trial.
O t h e r  i n v e s t i g a t i o n s  w i l l  b e  a t  t h e  d i s c r e t i o n  o f  t h e
managing physician.
Post discharge phone review
Will be undertaken for all patients 5 to 7 days post dis-
charge. Information collected will include return visits to
a hospital, admission to hospital, attendance at local
medical officer - planned and unplanned and other com-
plications including difficulty feeding, nasal sores, arm
bruising or sores.
Guidelines for oxygen therapy
• Oxygen should be commenced to keep SpO2 ≥ 92%, 
or if there is markedly increased work of breathing 
and respiratory distress.
• The least amount of oxygen needed to keep SpO2 ≥ 
92% should be administered.
• Oxygen should be ceased when SpO2 is consistently 
above 92%, and the child is able to feed well. Cease by 
weaning the flow as tolerated until 1 l/min or less is 
needed.
Guidelines for non-oral fluid commencement are pre-
sented in Table 1.
Guidelines for changing the treatment from one inter-
vention to the other are presented in Additional File 2.
Outcome measures
The primary outcome measure is the inpatient length of
stay. This will be recorded in 2 ways: 1) the actual dura-
tion of inpatient stay will be determined from the com-
puterised database of patient admission; 2) Given that the
length of stay can be affected by many administrative and
Table 1: Guidelines for commencement of non oral fluid 
therapy.
Weight (Kg) Fluid rate (mls/hr)
Intravenous Nasogastric
3.0 10 12
4.0 13 18
5.0 16 21
6.0 19 24
7.0 22 27
8.0 26 30
9.0 29 33
10 32 36
12 35 39
15 40 42
20 48 50
Note: total initial hydration rate is determined at about 80% 
maintenance fluid requirements, and should never exceed 100% 
of daily fluid requirements  BMC Pediatrics 2010, 10:37
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social factors unrelated to the condition of the child, we
will record and report also the time until the child is
ready for discharge using objective criteria. An infant will
be considered ready for discharge if he/she has not
received supplemental oxygen for 12 hours, has had sta-
ble respiratory status for 4 hours (including slight or nil
recession) and is feeding adequately.
The secondary outcome measures are the incidence
and type of complications of hydration therapy (compli-
cations will include any adverse event related to the
method of hydration, including but not limited to electro-
lyte abnormalities, IV line/NGT needing replacement,
infection, thrombosis of the IV site, trauma to the nose
from the NGT, pulmonary aspiration, extravasation of IV
fluid); the duration of therapy; parental satisfaction (mea-
sured daily) and an economic appraisal of each interven-
tion.
Sample size, power and statistical methods
The minimal clinically significant difference in length of
hospital stay was thought to be greater than or equal to 12
hours. In order to perform the sample size calculation we
determined mean duration of hospital stay and standard
deviation (sd) from two available sets of admitted patients
with bronchiolitis. Mean (sd) length of inpatient stay in a
retrospective review of 36 patients admitted with bron-
chiolitis and requiring fluid replacement was 84 (49)
hours. For the patients who were enrolled and ran-
domised in the pilot study, mean (sd) duration of admis-
sion was 98 (70) hours, suggesting that patients who enter
the study may have more severe illness.
Recruiting a total of 750 subjects (375 per arm) will give
80% power to detect an effect size of 0.2 (a small effect)
using a two group t-test with a 0.05 two-sided signifi-
cance level. That is a difference of 0.2 standard deviations
between the mean length of stay in the 2 groups. If the sd
is 70 hours (as in the pilot of the protocol), the study will
be able to detect a difference between the groups of 14
hours; if the sd is 50 hours (as in the retrospective
review), the study will be able to detect a difference of just
over 8 hours. Thus, this study is powered to detect a dif-
ference in duration of admission of 14 hours, and possibly
much less.
For the secondary outcomes, using this sample size, and
knowing that approximately 30% of all intravenous can-
nulae have been shown to have complications,[25-28]
gives 80% power to detect a 30% change in complications
(from 30% to 20%) with a 0.05 significance level.
Analysis will be by intention to treat. Data will be analy-
sed descriptively and statistically using the STATA data
analysis program. Since this is a RCT and 2 of the out-
come measures are measured on a continuous scale
(duration of inpatient stay or hours of therapy), t-tests
will be used to compare the 2 groups. If necessary due to
skewed data, the data will be log-transformed. Data on
parental satisfaction and complications will be treated as
categorical and a Chi-squared test will be used.
No interim analysis of the data is planned.
Economic evaluation
A trial-based economic evaluation will be conducted to
assess which approach to fluid replacement therapy is the
more 'cost-effective', as judged by their 'cost per child
ready for discharge' ratio. The appraisal will be a cost-
effectiveness analysis (i.e. outcomes measured with clini-
cally meaningful indicators) using decision tree analysis.
The choice of Cost Effective Analysis reflects the research
question - one of 'technical efficiency' (i.e. which treat-
ment approach to use) rather than 'allocative efficiency'
(i.e. whether treatment should be provided). The
appraisal will be conducted from a 'health sector perspec-
tive', but with a primary focus on the 'hospital as provider'
and 'government as 3rd party funder' perspectives.
Data collection for the economic appraisal is integrated
in the resource monitoring, process and outcome mea-
sures described above. On the cost side, pathway analysis
and patient flowcharts will be used to fully specify all
treatment activities (i.e. activity; probability of occur-
rence; no of times activity occurs; unit price). Resource
costs to be included in the study (e.g. ICU bed occupa-
tion, general hospital bed occupation, complications &
adverse events, tests & procedures, etc) will be fully spec-
ified in the economic evaluation protocol before the
study commences. The appraisal will include sensitivity
and uncertainty analysis (using the @Risk software) to
explore the impact on cost-effectiveness results of uncer-
tainty in cost and outcome data. Discounting will not be
relevant to this study as the time horizon is less than one
year.
Adverse experiences
All adverse experiences either observed by the investiga-
tor or one of the clinical staff, or reported by the patient's
parents/guardians spontaneously or in response to a
direct question, that occur during the study period or a
need for a change in therapy, will be evaluated by the
investigator and noted in the adverse experience section
of the patient's CRF. Events after the study period also
thought to be due to a study intervention will be included.
A serious adverse event (SAE) is generally defined as
any event that is fatal, life-threatening, permanently dis-
abling, incapacitating or results in hospitalisation, pro-
l o n g s  a  h o s p i t a l  s t a y  o r  i s  a s s o c i a t e d  w i t h  c o n g e n i t a l
abnormality, carcinoma or overdose.
Note: an event which is an expected and measured out-
come of the trial can be treated as an adverse event rather
than a serious adverse event (e.g. delayed discharge due to
an infected IV site is an adverse event not an SAE).  BMC Pediatrics 2010, 10:37
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Serious adverse events
For this trial, serious adverse events are the following:
• death during the study period
• aspiration pneumonitis associated with NG tube 
misplacement
• intrapulmonary infusion of fluid
• electrolyte disturbance causing seizure
• Any other event not mentioned above that is life 
threatening event or jeopardises the patient or 
requires medical or surgical intervention
Reporting SAEs
SAEs need to be reported within 24 hrs by telephone to
the local site investigator. The local investigator must
report the SAE to their local ethics committee within 48
hours (or in accordance with local ethics committee regu-
lations). The local investigator must also report SAEs to
the principal investigators who will report the event to
the Data Monitoring Committee chairman. The principal
investigator will also report the SAE to all Ethics Com-
mittees and other regulatory bodies involved in the trial
as per regional regulatory requirements.
S A E s  w i l l  a l s o  b e  r e p o r t e d  t o  t h e  c o n s u l t a n t  o f  t h e
child's treating team. The medical consultant will initiate
appropriate management and inform the family if the
family is not already aware of the event. This reporting is
the responsibility of the site investigator.
Limitations
This trial has a number of potential limitations. The
interventions could not be blinded and clinician or
researcher bias may influence clinical decision making.
However, with the documented rates of use of each inter-
vention approaching 50% - documented prior to the trial
23 -this is unlikely to significantly impact on the outcome.
Further, the trial is attempting to assess the use of the
interventions in the real world clinical environment
where these biases are in play, so the ability to translate
the trial results to actual clinical situations may actually
be improved. The environment where this study is being
performed has low use of ancillary medications (e.g.
bronchodilators and steroids) in bronchiolitis
patients[23]. Although subgroup analysis would be desir-
able, the sample size to achieve this would not be possible
within our study setting. The trial excludes children
under 8 weeks of age and any results will not be generalis-
able to this population. No scoring system is used in this
trial to determine severity, this remaining a clinical deci-
sion representing the real clinical environment, but may
inhibit reproduction of the results.
Discussion
The study commenced recruitment in mid 2009. Cur-
rently over 190 patients have been randomised. Patient
recruitment is expected to be completed by December
2011.
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